X-Linked Retinitis Pigmentosa emerging market size is expected to grow immensely with a significant CAGR during the study period (2020–2034).

X-Linked Retinitis Pigmentosa Market Size Analysis Report 2034 

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key Insights
2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Report Introduction
3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Executive Summary of XLRP
4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XLRP Market Overview at a Glance
4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Market Share by Therapies (%) Distribution of XLRP in 2020 in the 7MM
4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Market Share by Therapies (%) Distribution of XLRP in 2034 in the 7MM
5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key Events
6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epidemiology and Market Forecast Methodology
7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XLRP: Disease Background and Overview
7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Introduction
7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs and Symptoms
7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Causes of XLRP
7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Classification of XLRP
7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pathophysiology
7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diagnosis of XLRP
7.6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diagnostic Tests
7.6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Differential Diagnosis of XLRP
7.6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diagnostic Guidelines
7.6.3.1&nbsp;&nbsp; American Academy of Ophthalmology: Guidelines on Clinical Assessment of Patients With Inherited Retinal Degenerations - 2022
7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROGNOSIS
8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of XLRP
8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Future Treatment Modalities
8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General Recommendations for XLRP Treatment
8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment Guidelines for XLRP
8.3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment Guidelines Yoshimune et al. (2017)
8.3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment Recommendations as suggested by Gallemore et al. (2017)
9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epidemiology and Patient Population
9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key Findings
9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assumptions and Rationale
9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Prevalent Cases of XLRP in the 7MM
9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The United States
9.4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Prevalent Cases of Retinitis Pigmentosa in the US
9.4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Prevalent Cases of XLRP in the United States
9.4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gender-specific Cases of XLRP in the United States
9.4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age-specific Cases of XLRP in the United States
9.4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevalence of XLRP by Mutant Genes in the United States
9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EU4 and the UK
9.5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Prevalent Cases of Retinitis Pigmentosa in EU4 and the UK
9.5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Prevalent Cases of XLRP in EU4 and the UK
9.5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gender-specific Cases of XLRP in EU4 and the UK
9.5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age-specific Cases of XLRP in EU4 and the UK
9.5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevalence of XLRP by Mutant Genes in EU4 and the UK
9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; JAPAN
9.6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Prevalent Cases of Retinitis Pigmentosa in Japan
9.6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Prevalent Cases of XLRP in Japan
9.6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gender-specific Cases of XLRP in Japan
9.6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age-specific Cases of XLRP in Japan
9.6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevalence of XLRP by Mutant Genes in Japan
10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Journey
11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emerging Drugs
11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key Competitors
11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AGTC-501: Beacon Therapeutics
11.2.1&nbsp;&nbsp;&nbsp; Product Description
11.2.2&nbsp;&nbsp;&nbsp; Other Developmental Activities
11.2.3&nbsp;&nbsp;&nbsp; Clinical Developmental Activities
11.2.4&nbsp;&nbsp;&nbsp; Safety and Efficacy
11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4D-125: 4D Molecular Therapeutics
11.3.1&nbsp;&nbsp;&nbsp; Product Description
11.3.2&nbsp;&nbsp;&nbsp; Other Development Activities
11.3.3&nbsp;&nbsp;&nbsp; Clinical Developmental Activities
11.3.4&nbsp;&nbsp;&nbsp; Safety and Efficacy
11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Botaretigene sparoparvovec (AAV-RPGR): MeiraGTx/ Johnson &amp; Johnson Innovative Medicine
11.4.1&nbsp;&nbsp;&nbsp; Product Description
11.4.2&nbsp;&nbsp;&nbsp; Other Development Activities
11.4.3&nbsp;&nbsp;&nbsp; Clinical Developmental Activities
11.4.4&nbsp;&nbsp;&nbsp; Safety and Efficacy
12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XLRP: Market Analysis
12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key Findings
12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Market Outlook
12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjoint Analysis
12.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key Market Forecast Assumptions
12.4.1&nbsp;&nbsp;&nbsp; Cost Assumptions and Rebates
12.4.2&nbsp;&nbsp;&nbsp; Pricing Trends
12.4.3&nbsp;&nbsp;&nbsp; Analogue Assessment
12.4.4&nbsp;&nbsp;&nbsp; Launch Year and Therapy Uptakes
12.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Market Size of XLRP in the 7MM
12.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States Market Size
12.6.1&nbsp;&nbsp;&nbsp; Total Market Size of XLRP in the United States
12.6.2&nbsp;&nbsp;&nbsp; Market Size of XLRP by Therapies in the United States
12.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EU4 and the UK Market Size
12.7.1&nbsp;&nbsp;&nbsp; Total Market Size of XLRP in EU4 and the UK
12.7.2&nbsp;&nbsp;&nbsp; Market Size of XLRP by Therapies in EU4 and the UK
12.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan Market Size
12.8.1&nbsp;&nbsp;&nbsp; Total Market Size of XLRP in Japan
12.8.2&nbsp;&nbsp;&nbsp; Market Size of XLRP by Therapies in Japan
13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNMET NEEDS
14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SWOT ANALYSIS
15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KOL VIEWS
16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKET ACCESS AND REIMBURSEMENT
16.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States
16.1.1&nbsp;&nbsp;&nbsp; Centre for Medicare and Medicaid Services (CMS)
16.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EU4 AND THE UK
16.2.1&nbsp;&nbsp;&nbsp; Germany
16.2.2&nbsp;&nbsp;&nbsp; France
16.2.3&nbsp;&nbsp;&nbsp; Italy
16.2.4&nbsp;&nbsp;&nbsp; Spain
16.2.5&nbsp;&nbsp;&nbsp; United Kingdom
16.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan
16.3.1&nbsp;&nbsp;&nbsp; MHLW
16.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Market Access and Reimbursement of XLRP
17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; APPENDIX
17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bibliography
17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Report Methodology
18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DELVEINSIGHT CAPABILITIES
18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DISCLAIMER
19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ABOUT DELVEINSIGHT

DelveInsight's “X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of historical and forecasted epidemiology as well as the XLRP therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

X-Linked Retinitis Pigmentosa Market

X-Linked Retinitis Pigmentosa Market Insight, Epidemiology And Market Forecast - 2034

DelveInsight's X-Linked Retinitis Pigmentosa Market Insights, Epidemiology-2034" report delivers an in-depth understanding of the historical data and market forecast.
